Working… Menu

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04590664
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : February 17, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
William Read, Emory University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 15, 2023
Estimated Study Completion Date : August 15, 2023